Subscribe to RSS
DOI: 10.1055/s-0041-1728801
A Series of Nontuberculous Mycobacterial Flexor Tenosynovitis Infections and Cost of Treatment
Funding None.![](https://www.thieme-connect.de/media/jws/202106/lookinside/thumbnails/10-1055-s-0041-1728801_2000159cra-1.jpg)
Abstract
Background Nontuberculous mycobacteria (NTM) are rare but potentially devastating causes of musculoskeletal infection and impairment in immunocompetent patients.
Purpose Given the sparse body of literature surrounding these infections, we describe a series of patients with and the cost of treatment of upper extremity NTM infections.
Patients and Methods In a retrospective review of seven patients with NTM infections of the upper extremity treated at a university hospital from 2010 to 2019, we assessed patient demographics, exposures, infection characteristics, management course, outcomes, and costs of treatment.
Results Insidious pain and swelling were the most common clinical manifestation of infection. Despite coupled surgical and medical management, recurrence was common. Two patients required amputation, and three others had lasting functional deficits. The most common pathogen was Mycobacterium avium complex (5 of 7). The estimated median charge related to management was $85,126 with a range from $8,361 to $1,66,229.
Conclusions The treatment of NTM infections is complex and expensive. Diagnosis is usually delayed, which further complicates the management of these patients who often suffer from lasting debilitation. Due to its potentially devastating course, NTM infection should be considered and tested for whenever flexor tenosynovitis is suspected. Regardless of initial presentation, our experience suggests that a protocol of serial surgical debridement immediately after tissue diagnosis is necessary for optimal outcomes. Furthermore, NTM infections require collaboration with infectious disease colleagues to guide antimicrobial regimens based on susceptibility testing and therapeutic drug monitoring for the recommended 6 to 12 months of therapy after the final operative debridement.
Level of Evidence This is a Level IV, case series study.
Keywords
cost analysis - Mycobacterium immunogenum - upper extremity infections - flexor tenosynovitis - nontuberculous mycobacteriaEthical Approval
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. No identifiable information of the patient was included in this case series; therefore, informed consent was not required.
The cases described were managed at the University of Virginia
Publication History
Received: 20 November 2020
Accepted: 04 March 2021
Article published online:
04 May 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Falkinham JO. Epidemiology of Infection by Nontuberculous Mycobacteria. Accessed March 25, 2021 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC172890/pdf/090177.pdf 1996
- 2 Jiang L-D, Chiou H-J, Wu H-D. et al. Nontuberculous mycobacterial tenosynovitis: a case report and review of the literature. J Med Ultrasound 2015; 23: 199-203
- 3 Yao A, Sia TY, Fong D. Mycobacterium marinum and carpal tunnel syndrome: three case reports. J Hand Surg Am 2017; 42 (12) 1037.e1-1037.e5
- 4 Chau CLF, Griffith JF, Chan PT, Lui TH, Yu KS, Ngai WK. Rice-body formation in atypical mycobacterial tenosynovitis and bursitis: findings on sonography and MR imaging. AJR Am J Roentgenol 2003; 180 (05) 1455-1459
- 5 Mateo L, Rufí G, Nolla JM, Alcaide F. Mycobacterium chelonae tenosynovitis of the hand. Semin Arthritis Rheum 2004; 34 (03) 617-622
- 6 Sanal HT, Zor F, Kocaoğlu M, Bulakbaşi N. Atypical mycobacterial tenosynovitis and bursitis of the wrist. Diagn Interv Radiol 2009; 15 (04) 266-268
- 7 Ehrlichman LK, Kadzielski JJ, Hyle EP, Jupiter JB. Nontuberculous mycobacterial osteomyelitis of the thumb: successful treatment with serial debridement, antimicrobial therapy, external fixation, and interphalangeal arthrodesis: a case report. JBJS Case Connect 2015; 5 (04) e87
- 8 Yano K, Yoshida T, Minoda Y. et al. Clinical outcome of the chronic flexor tenosynovitis in the hand caused by non-tuberculous mycobacterium treated by extensive tenosynovectomy and drugs. J Plast Surg Hand Surg 2013; 47 (06) 434-437
- 9 Draeger RW, Bynum Jr DK. Flexor tendon sheath infections of the hand. J Am Acad Orthop Surg 2012; 20 (06) 373-382
- 10 Stern PJ, Gula DC. Mycobacterium chelonae tenosynovitis of the hand: a case report. J Hand Surg Am 1986; 11 (04) 596-599
- 11 Kozin SH, Bishop AT. Atypical Mycobacterium infections of the upper extremity. J Hand Surg Am 1994; 19 (03) 480-487
- 12 Sotello D, Garner HW, Heckman MG, Diehl NN, Murray PM, Alvarez S. Nontuberculous mycobacterial infections of the upper extremity: 15-year experience at a tertiary care medical center. J Hand Surg Am 2018; 43 (04) 387.e1-387.e8
- 13 Cheung JPY, Fung B, Ip WY, Chow SP. Mycobacterium marinum infection of the hand and wrist. J Orthop Surg (Hong Kong) 2012; 20 (02) 214-218
- 14 Hsiao CH, Cheng A, Huang YT, Liao CH, Hsueh PR. Clinical and pathological characteristics of mycobacterial tenosynovitis and arthritis. Infection 2013; 41 (02) 457-464
- 15 Napaumpaiporn C, Katchamart W. Clinical manifestations and outcomes of musculoskeletal nontuberculous mycobacterial infections. Rheumatol Int 2019; 39 (10) 1783-1787
- 16 Horsburgh CR. Epidemiology of Mycobacterium avium complex disease. Am J Med 1997; 102: 11-15
- 17 Park JW, Kim YS, Yoon JO. et al. Non-tuberculous mycobacterial infection of the musculoskeletal system: pattern of infection and efficacy of combined surgical/antimicrobial treatment. Bone Joint J 2014; 96-B (11) 1561-1565
- 18 Zenone T, Boibieux A, Tigaud S. et al. Non-tuberculous mycobacterial tenosynovitis: a review. Scand J Infect Dis 1999; 31 (03) 221-228
- 19 Cheung JP, Fung B, Wong SS, Ip WY. Review article: Mycobacterium marinum infection of the hand and wrist. J Orthop Surg (Hong Kong) 2010; 18 (01) 98-103
- 20 Shenoy A, El-Nahal W, Walker M. et al. Management of a Mycobacterium immunogenum infection of a peritoneal dialysis catheter site. Infection 2018; 46 (06) 875-880
- 21 Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 2012; 27 (8, Suppl): 61-5.e1
- 22 Brown-Elliott BA, Hanson K, Vasireddy S. et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. J Clin Microbiol 2015; 53 (03) 875-878
- 23 Griffith DE, Aksamit T, Brown-Elliott BA. et al; ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175 (04) 367-416